Phase II dose ranging study to evaluate the anti-mycotic efficacy of topical Abafungin formulations in patients with tinea pedis.

Registry ID

EUCTR2005-002842-20

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

York Pharma GmbH

Start date

2005-09-14

Completion date

2006-12-12

Last update

2026-08-16

Conditions

• patients

Summary

To compare the efficacy of Abafungin cream 0.2 %, Abafungin cream 1.0 %, Abafungin cream 2.0 % and vehicle to Abafungin cream, applied once daily for 4 weeks in patients with interdigital tinea pedis.

Locations

• , , Germany

View on source registry